Bayer's pharma chief hopes EU takes time to improve drug rules reform
Shorter drug exclusivity 'catastrophic' -Bayer executive Oelrich
Oelrich says U.S. market more attractive than Europe
Warns that IRA rules could lead to fewer drug use cases
Adds comment on new U.S. drug pricing rules
By Ludwig Burger and Patricia Weiss
FRANKFURT, March 24 (Reuters) -The European Union's decision to postpone rule changes for the pharmaceutical industry could open the way for a rethink of a decision to cut intellectual drug property protection, the head of Bayer's BAYGn.DE pharmaceuticals division said.
The European Commission said this week that the publication of a first draft of a planned revision of drug legislation in the bloc would be "slightly later" than March 29, as initially planned.
A version that was leaked earlier this year showed that Brussels was preparing to shorten an additional period of intellectual property protection, known as data exclusivity, which comes on top of drug patent protection.
"I hope that this delay means that there is an opportunity that this draft ... is not the final version," the head of Bayer's pharmaceuticals business, Stefan Oelrich, told Reuters on Friday.
"The duration of data exclusivity, which may be reduced, could actually have a catastrophic impact for Europe," he said.
Shaving one or two years off the exclusivity period could mean that pharma companies pull the plug on certain development projects for the region, he added.
He said the intentions of Brussels lawmakers - improving patient access to innovative drugs while making the European pharma sector more competitive - were noble but any shortening of intellectual property protection would have the opposite effect.
'HIGHLY ATTRACTIVE'
In the United States, a different set of drug market rule changes are underway, with some of the highest-selling products set to see negotiated price discounts under the Inflation Reduction Act (IRA).
Oelrich said even so the U.S. market would remain "highly attractive, relative to Europe".
Bayer is looking to boost the U.S. share of its global pharmaceuticals sales, now at about 25%. Among the biggest drivers was the company's decision to prepare a U.S. launch of its next-generation stroke prevention drug asundexian on its own.
With asundexian, which will likely see pivotal trial results in 2025 or 2026, Bayer is seeking to follow up on the success of its blood thinner Xarelto, a drug for which the company ceded most of the U.S. rights to partner Johnson & Johnson JNJ.N.
But Oelrich said upcoming U.S. legislation to regulate the prices of best-selling drugs after nine years or 13 years, depending on the drug category, would have an affect on the industry's strategy to develop several uses for a given drug, known as indications.
The IRA could "have an impact on whether additional indications are to be developed for certain products. People will look into whether they bring this forward or just refrain from further development" said Oelrich.
Bayer shares laghttps://tmsnrt.rs/3lFAcNA
Reporting by Ludwig Burger; editing by Jonathan Oatis and Jane Merriman
Actifs liés
Dernières actualités
Avertissement : Les entités de XM Group proposent à notre plateforme de trading en ligne un service d'exécution uniquement, autorisant une personne à consulter et/ou à utiliser le contenu disponible sur ou via le site internet, qui n'a pas pour but de modifier ou d'élargir cette situation. De tels accès et utilisation sont toujours soumis aux : (i) Conditions générales ; (ii) Avertissements sur les risques et (iii) Avertissement complet. Un tel contenu n'est par conséquent fourni que pour information générale. En particulier, sachez que les contenus de notre plateforme de trading en ligne ne sont ni une sollicitation ni une offre de participation à toute transaction sur les marchés financiers. Le trading sur les marchés financiers implique un niveau significatif de risques pour votre capital.
Tout le matériel publié dans notre Centre de trading en ligne est destiné à des fins de formation / d'information uniquement et ne contient pas – et ne doit pas être considéré comme contenant – des conseils et recommandations en matière de finance, de fiscalité des investissements ou de trading, ou un enregistrement de nos prix de trading ou une offre, une sollicitation, une transaction à propos de tout instrument financier ou bien des promotions financières non sollicitées à votre égard.
Tout contenu tiers, de même que le contenu préparé par XM, tels que les opinions, actualités, études, analyses, prix, autres informations ou liens vers des sites tiers contenus sur ce site internet sont fournis "tels quels", comme commentaires généraux sur le marché et ne constituent pas des conseils en investissement. Dans la mesure où tout contenu est considéré comme de la recherche en investissement, vous devez noter et accepter que le contenu n'a pas été conçu ni préparé conformément aux exigences légales visant à promouvoir l'indépendance de la recherche en investissement et, en tant que tel, il serait considéré comme une communication marketing selon les lois et réglementations applicables. Veuillez vous assurer que vous avez lu et compris notre Avis sur la recherche en investissement non indépendante et notre avertissement sur les risques concernant les informations susdites, qui peuvent consultés ici.
